The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process
Abstract
Primary sclerosing cholangitis (PSC) is a rare, but serious, cholestatic disease for which, to date, no effective therapy exists to halt disease progression toward end‐stage liver disease. Clinical trial design to study drugs that improve prognosis is hampered by the relatively low event rate of clinically relevant endpoints. To overcome this shortcoming, there is an urgent need to identify appropriate surrogate endpoints. At present, there are no established surrogate endpoints. This article provides a critical review and describes the results of a consensus process initiated by the International PSC Study Group to delineate appropriate candidate surrogate endpoints at present for clinical trials in this frequently dismal disease. The consensus process resulted in a shortlist of five candidates as surrogate endpoints for measuring disease progression: alkaline phosphatase (ALP); transient elastography (TE); histology; combination of ALP+histology; and bilirubin. Of these, histology, ALP, and TE came out as the most promising. However, the expert panel concluded that no biomarker currently exceeds level 3 validation. Combining multiple endpoints is advisable. Conclusion: At present, there are insufficient data to support level 2 validation for any surrogate endpoint in PSC. Concerted efforts by all stakeholders are highly needed. Novel, promising noninvasive biomarkers are under study and should be incorporated as exploratory endpoints in clinical trials. (H epatology 2016;63:1357–1367)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus methods: characteristics and guidelines for use
Fink, A., Kosecoff, J., Chassin, M., & Brook, R. H. (1984) · American Journal of Public Health · doi:10.2105/ajph.74.9.979 · Cited by 2,089
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870
Boonstra, K., Weersma, R. K., van Erpecum, K. J., Rauws, E. A., Spanier, B. W. M., Poen, A. C., van Nieuwkerk, K. M., Drenth, J. P., Witteman, B. J., Tuynman, H. A., et al. (2013) · Hepatology · doi:10.1002/hep.26565 · Cited by 725
Self-citationUrsodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Olsson, R., Boberg, K. M., Schaffalitsky de Muckadell, O., Lindgren, S., Hultcrantz, R., Folvik, G., Bell, H., Gangsøy–Kristiansen, M., Matre, J., Rydning, A., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.017 · Cited by 394
Corpechot, C., Gaouar, F., El Naggar, A., Kemgang, A., Wendum, D., Poupon, R., Carrat, F., & Chazouillères, O. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.030 · Cited by 300
Self-citationTabibian, J. H., Weeding, E., Jorgensen, R. A., Petz, J. L., Keach, J. C., Talwalkar, J. A., & Lindor, K. D. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12232 · Cited by 267
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis
Harnois, D. M., Angulo, P., Jorgensen, R. A., LaRusso, N. F., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03777.x · Cited by 242
Färkkilä, M., Karvonen, A., Nurmi, H., Nuutinen, H., Taavitsainen, M., Pikkarainen, P., & Kärkkäinen, P. (2004) · Hepatology · doi:10.1002/hep.20457 · Cited by 218
Cited by
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Primary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868
Self-citationPrimary Sclerosing Cholangitis
Lazaridis, K. N., & LaRusso, N. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1506330 · Cited by 505
Primary sclerosing cholangitis
Dyson, J. K., Beuers, U., Jones, D. E. J., Lohse, A. W., & Hudson, M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30300-3 · Cited by 462
Self-citationEASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Self-citationnorUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.009 · Cited by 297
Chapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317993 · Cited by 284
Self-citationTrauner, M., Gulamhusein, A., Hameed, B., Caldwell, S., Shiffman, M. L., Landis, C., Eksteen, B., Agarwal, K., Muir, A., Rushbrook, S., et al. (2019) · Hepatology · doi:10.1002/hep.30509 · Cited by 261
Self-citationAllegretti, J. R., Kassam, Z., Carrellas, M., Mullish, B. H., Marchesi, J. R., Pechlivanis, A., Smith, M., Gerardin, Y., Timberlake, S., Pratt, D. S., et al. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000115 · Cited by 234
Muir, A. J., Levy, C., Janssen, H. L. A., Montano‐Loza, A. J., Shiffman, M. L., Caldwell, S., Luketic, V., Ding, D., Jia, C., McColgan, B. J., et al. (2019) · Hepatology · doi:10.1002/hep.30237 · Cited by 195
Hirschfield, G. M., Chazouillères, O., Drenth, J. P., Thorburn, D., Harrison, S. A., Landis, C. S., Mayo, M. J., Muir, A. J., Trotter, J. F., Leeming, D. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.035 · Cited by 187
Self-citationPape, S., Snijders, R. J. A. L. M., Gevers, T. J. G., Chazouilleres, O., Dalekos, G. N., Hirschfield, G. M., Lenzi, M., Trauner, M., Manns, M. P., Vierling, J. M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.041 · Cited by 177
Self-citationGenetics of primary sclerosing cholangitis and pathophysiological implications
Jiang, X., & Karlsen, T. H. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.154 · Cited by 155
Self-citationPromises of microbiome-based therapies
Bajaj, J. S., Ng, S. C., & Schnabl, B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.003 · Cited by 119
Lynch, K. D., Chapman, R. W., Keshav, S., Montano-Loza, A. J., Mason, A. L., Kremer, A. E., Vetter, M., de Krijger, M., Ponsioen, C. Y., Trivedi, P., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.013 · Cited by 105
Self-citationPonsioen, C. Y., Assis, D. N., Boberg, K. M., Bowlus, C. L., Deneau, M., Thorburn, D., Aabakken, L., Färkkilä, M., Petersen, B., Rupp, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.046 · Cited by 95
Self-citationde Vries, E. M. G., Färkkilä, M., Milkiewicz, P., Hov, J. R., Eksteen, B., Thorburn, D., Chazouillères, O., Pares, A., Nygård, S., Gilja, O. H., et al. (2017) · Liver International · doi:10.1111/liv.13402 · Cited by 83
Self-citationLemoinne, S., Pares, A., Reig, A., Ben Belkacem, K., Kemgang Fankem, A. D., Gaouar, F., Poupon, R., Housset, C., Corpechot, C., & Chazouillères, O. (2018) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2018.06.009 · Cited by 74
Self-citationEaton, J. E., Sen, A., Hoodeshenas, S., Schleck, C. D., Harmsen, W. S., Gores, G. J., LaRusso, N. F., Gossard, A. A., Lazaridis, K. N., & Venkatesh, S. K. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.10.041 · Cited by 56
Self-citationTrivedi, P. J., Muir, A. J., Levy, C., Bowlus, C. L., Manns, M. P., Lu, X., Crans, G., Chung, C., Subramanian, G. M., Myers, R. P., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.07.032 · Cited by 55
Self-citationEffects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis
Hedin, C. R. H., Sado, G., Ndegwa, N., Lytvyak, E., Mason, A., Montano-Loza, A., Gerussi, A., Saffioti, F., Thorburn, D., Nilsson, E., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.02.014 · Cited by 52
Self-citationImmunobiology of primary sclerosing cholangitis
Cornillet, M., Geanon, D., Bergquist, A., & Björkström, N. K. (2025) · Hepatology · doi:10.1097/hep.0000000000001080 · Cited by 20
Metadata
- Authors
- Ponsioen, C. Y., Chapman, R. W., Chazouillères, O., Hirschfield, G. M., Karlsen, T. H., Lohse, A. W., Pinzani, M., Schrumpf, E., Trauner, M., & Gores, G. J.
- Venue
- Hepatology
- Published
- 2015-12-23
- Volume
- 63
- Issue
- 4
- Pages
- 1357-1367
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2102005215
- Cited by
- 179
- References
- 15
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.